Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Account Payables: 2011-2025

Historic Change in Account Payables for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to -$938,000.

  • Niagen Bioscience's Change in Account Payables rose 21.96% to -$938,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 382.27%. This contributed to the annual value of -$1.1 million for FY2024, which is 292.95% down from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Change in Account Payables is -$938,000, which was down 130.77% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Change in Account Payables ranged from a high of $3.0 million in Q2 2025 and a low of -$2.3 million during Q1 2024.
  • For the 3-year period, Niagen Bioscience's Change in Account Payables averaged around $336,545, with its median value being $206,000 (2024).
  • Its Change in Account Payables has fluctuated over the past 5 years, first crashed by 229.26% in 2022, then surged by 1,379.61% in 2025.
  • Niagen Bioscience's Change in Account Payables (Quarterly) stood at -$381,000 in 2021, then surged by 246.98% to $560,000 in 2022, then skyrocketed by 84.64% to $1.0 million in 2023, then skyrocketed by 118.76% to $2.3 million in 2024, then rose by 21.96% to -$938,000 in 2025.
  • Its last three reported values are -$938,000 in Q3 2025, $3.0 million for Q2 2025, and $2.1 million during Q1 2025.